Does Insulin analogs work?
Yes, in large controlled trials, including one of 756 adults.
Every insulin analog was approved on randomised trials against human insulin. The cited Treat-to-Target trial randomised 756 adults with type 2 diabetes to glargine or NPH insulin added to oral drugs for 24 weeks and found the same glucose control with fewer night-time lows on glargine. 23
In the Treat-to-Target trial, Riddle and colleagues randomised 756 overweight adults with type 2 diabetes. Their diabetes was poorly controlled on oral drugs. They got bedtime glargine or NPH for 24 weeks, both adjusted to a fasting glucose goal. Nearly 60% of each group reached an HbA1c of 7% or below. Glargine caused significantly less night-time hypoglycaemia. Rates of other kinds of symptomatic hypoglycaemia were 21 to 48% lower. About 25% more patients on glargine (33.2% against 26.7%) reached the HbA1c goal without a documented night-time low. 2
In type 1 diabetes, rapid-acting analogs gave modest drops in post-meal glucose and hypoglycaemia against regular human insulin. HbA1c differed little. So their main advantage is practical: people can inject right before eating. 3
Evidence checklist
- Randomised controlled trial Treat-to-Target and other randomized trials
- Human study over 100 people Treat-to-Target, 756 adults
- More than one research group Many trials, products, and sponsors
- Clinical outcomes, not surrogate markers HbA1c and night lows, not complications
- Human safety data beyond case reports Decades of use; ORIGIN found no cancer signal
Read the full Insulin analogs page
More on Insulin analogs
Citations
- Novo Nordisk: Levemir (insulin detemir) discontinuation information novocare.com
- Riddle 2003, Diabetes Care: the Treat-to-Target trial, glargine versus NPH added to oral therapy in type 2 diabetes doi.org
- Eli Lilly: Humalog (insulin lispro) prescribing information uspl.lilly.com
Reference information only, not medical advice. Drawn from the Insulin analogs article, fact-checked against the cited sources. No dosing anywhere on this site.